Cytokinetics, Incorporated KK3A.F Stock
Cytokinetics, Incorporated Price Chart
Cytokinetics, Incorporated KK3A.F Financial and Trading Overview
| Cytokinetics, Incorporated stock price | 68 EUR |
| Previous Close | 32.6 EUR |
| Open | 32.2 EUR |
| Bid | 32.2 EUR x 36600 |
| Ask | 32.8 EUR x 35200 |
| Day's Range | 32.2 - 32.2 EUR |
| 52 Week Range | 28.6 - 55 EUR |
| Volume | 200 EUR |
| Avg. Volume | 3 EUR |
| Market Cap | 3.1B EUR |
| Beta (5Y Monthly) | 0.797183 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -5.08 EUR |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 45.3 EUR |
KK3A.F Valuation Measures
| Enterprise Value | 3.17B EUR |
| Trailing P/E | N/A |
| Forward P/E | -9.470588 |
| PEG Ratio (5 yr expected) | -0.71 |
| Price/Sales (ttm) | 31.652044 |
| Price/Book (mrq) | N/A |
| Enterprise Value/Revenue | 32.296 |
| Enterprise Value/EBITDA | -8.688 |
Trading Information
Cytokinetics, Incorporated Stock Price History
| Beta (5Y Monthly) | 0.797183 |
| 52-Week Change | -13.90% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 55 EUR |
| 52 Week Low | 28.6 EUR |
| 50-Day Moving Average | 33.98 EUR |
| 200-Day Moving Average | 40.24 EUR |
KK3A.F Share Statistics
| Avg. Volume (3 month) | 3 EUR |
| Avg. Daily Volume (10-Days) | 0 EUR |
| Shares Outstanding | 95.64M |
| Float | 94.85M |
| Short Ratio | N/A |
| % Held by Insiders | 0.85% |
| % Held by Institutions | 115.10% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:6 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -378.18% |
| Gross Margin | -179.74% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -26.54% |
| Return on Equity (ttm) | N/A |
Income Statement
| Revenue (ttm) | 98.05M EUR |
| Revenue Per Share (ttm) | 1.06 EUR |
| Quarterly Revenue Growth (yoy) | 301.79% |
| Gross Profit (ttm) | -146225000 EUR |
| EBITDA | -364496992 EUR |
| Net Income Avi to Common (ttm) | -430799008 EUR |
| Diluted EPS (ttm) | -4.18 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 663.96M EUR |
| Total Cash Per Share (mrq) | 6.94 EUR |
| Total Debt (mrq) | 751.06M EUR |
| Total Debt/Equity (mrq) | N/A |
| Current Ratio (mrq) | 9.049 |
| Book Value Per Share (mrq) | -2.395 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -394991008 EUR |
| Levered Free Cash Flow (ttm) | -209217632 EUR |
Profile of Cytokinetics, Incorporated
| Country | Germany |
| State | CA |
| City | South San Francisco |
| Address | 350 Oyster Point Boulevard |
| ZIP | 94080 |
| Phone | 650 624 3000 |
| Website | https://www.cytokinetics.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 409 |
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure; and reldesemtiv, a skeletal muscle troponin activator, which is in Phase III clinical trial to treat amyotrophic lateral sclerosis and spinal muscular atrophy. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Astellas Pharma Inc. The company was incorporated in 1997 and is headquartered in South San Francisco, California.
Q&A For Cytokinetics, Incorporated Stock
What is a current KK3A.F stock price?
Cytokinetics, Incorporated KK3A.F stock price today per share is 68 EUR.
How to purchase Cytokinetics, Incorporated stock?
You can buy KK3A.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Cytokinetics, Incorporated?
The stock symbol or ticker of Cytokinetics, Incorporated is KK3A.F.
Which industry does the Cytokinetics, Incorporated company belong to?
The Cytokinetics, Incorporated industry is Biotechnology.
How many shares does Cytokinetics, Incorporated have in circulation?
The max supply of Cytokinetics, Incorporated shares is 104.58M.
What is Cytokinetics, Incorporated Price to Earnings Ratio (PE Ratio)?
Cytokinetics, Incorporated PE Ratio is now.
What was Cytokinetics, Incorporated earnings per share over the trailing 12 months (TTM)?
Cytokinetics, Incorporated EPS is -5.08 EUR over the trailing 12 months.
Which sector does the Cytokinetics, Incorporated company belong to?
The Cytokinetics, Incorporated sector is Healthcare.